Marco Alings, MD, PhD, FESC, is a practising cardiologist/electrophysiologist and director of the cardiology training program at the Amphia Ziekenhuis, Breda, the Netherlands. After obtaining his PhD in the field of cellular electrophysiology, Dr Alings earned a medical degree at the University of Amsterdam. He was trained in clinical cardiology at the Academic Medical Center (Amsterdam) and the University Medical Center Utrecht, and served as a post-doctoral fellow in molecular cardiology at Vanderbilt University, Nashville, TN under the supervision of Prof Dan M Roden.
In 2005, he joined the Board of the Werkgroep Cardiologische Centra Nederland (WCN), an association of 55 cardiovascular research centres, and served as Chair of the WCN from 2007 through 2013.
In 2014, Dr Alings joined Julius Clinical, an academic clinical research organisation specialised in executing global cardiovascular outcomes studies. Dr Alings is a clinical trialist, with a special interest in arrhythmias and stroke prevention, who served as national coordinator for many large international multicentre studies. He was actively involved in the Phase III NOAC stroke prevention trials. His clinical expertise and research experience lie in the areas of arrhythmias, heart failure, stroke prevention, lipid management and cardiac implantable electronic devices.
Currently, Dr Alings is (co-)principal investigator of 3 multicentre randomised trials: detection of subclinical atrial fibrillation, stroke prevention in device detected atrial fibrillation, and upstream therapy in atrial fibrillation. Additionally he serves as the national lead for two international multicentre cardiovascular outcome trials.
In the clinic, he is putting into practice the concept of a cluster randomized effectiveness trial to study the effect of different antibiotic regimes to prevent pocket infections of cardiovascular electronic implantable devices. Dr Alings closely cooperates with a number of international research networks including: Population Health Research Institute (Hamilton, Canada), Duke Clinical Research Institute (Durham, USA), and Uppsala Clinical Research Centre (Uppsala, Sweden).